6[4]Moise PA,Birmingham MC,Schentag JJ.Pharmacokineticsand Metabolism of Moxifloxacin[J].Drugs of Today,2000,36(4):229-244.
7Satoh Y, Sugiyama A,Chiba K, et al. QT prolonging effects of spaffloxacin, a fluoroquinolone antibiotic, assessed in the in vivo canine model with monophasis action potential monitoring [J]. J Cardiovasc Pharmacol, 2000 , 36 (4):510
8Bertino JS,Owens RC,Carnes TD, et al. Gatifloxacin-associared corrected QT interval prolongation, torsade de pointes, and ventricular fibrillation in patients with know risk factors. [J]. Clin Infect Dis ,2002,34(6):861
